Septerna Inc
SEPN12.130USD
-0.080-0.66%
交易中 （美東）報價延遲15分鐘
539.16M總市值
虧損本益比TTM
關於 Septerna Inc 公司
Septerna, Inc. 是一家臨牀階段的生物技術公司。該公司正在開發由其專有的 Native Complex Platform 支持的 G 蛋白偶聯受體 (GPCR) 口服小分子藥物發現。其候選產品管線專注於治療三個治療領域的患者：內分泌學、免疫學和炎症以及代謝疾病。其工業規模的 Native Complex Platform 旨在首次針對某些 GPCR，發現經過驗證的受體的新型結合位點，並尋求廣泛的藥理學，包括激動劑、拮抗劑和變構調節劑，以實現預期的治療效果。該公司正在推進一系列口服小分子 GPCR 靶向項目，採用新穎的機制方法治療多個治療領域的疾病，以滿足未滿足需求的患者的需求。該公司專注於主要治療領域，例如神經病學、女性健康、心血管和呼吸系統疾病。
公司簡介
公司代碼SEPN
公司名稱Septerna Inc
上市日期Oct 25, 2024
CEODr. Jeffrey (Jeff) Finer, M.D., Ph.D.
員工數量75
證券類型Ordinary Share
年結日Oct 25
公司地址250 East Grand Avenue, Suite 65
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94080
電話16503383533
網址https://septerna.com/
公司代碼SEPN
上市日期Oct 25, 2024
CEODr. Jeffrey (Jeff) Finer, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
826.91K
-12.75%
Dr. Alan Ezekowitz, M.D., Ph.D.
Dr. Alan Ezekowitz, M.D., Ph.D.
Director
Director
117.42K
-22.44%
Dr. Uwe Klein, Ph.D.
Dr. Uwe Klein, Ph.D.
Senior Vice President - Biological Sciences
Senior Vice President - Biological Sciences
112.65K
--
Mr. Daniel (Dan) Long
Mr. Daniel (Dan) Long
Senior Vice President - Drug Discovery
Senior Vice President - Drug Discovery
101.04K
--
Ms. Samira Shaikhly
Ms. Samira Shaikhly
Chief People Officer
Chief People Officer
36.81K
--
Mr. Gil Labrucherie
Mr. Gil Labrucherie
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
--
--
Mr. Abraham (Abe) Bassan
Mr. Abraham (Abe) Bassan
Independent Director
Independent Director
--
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
--
-100.00%
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
826.91K
-12.75%
Dr. Alan Ezekowitz, M.D., Ph.D.
Dr. Alan Ezekowitz, M.D., Ph.D.
Director
Director
117.42K
-22.44%
Dr. Uwe Klein, Ph.D.
Dr. Uwe Klein, Ph.D.
Senior Vice President - Biological Sciences
Senior Vice President - Biological Sciences
112.65K
--
Mr. Daniel (Dan) Long
Mr. Daniel (Dan) Long
Senior Vice President - Drug Discovery
Senior Vice President - Drug Discovery
101.04K
--
Ms. Samira Shaikhly
Ms. Samira Shaikhly
Chief People Officer
Chief People Officer
36.81K
--
Mr. Gil Labrucherie
Mr. Gil Labrucherie
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Third Rock Ventures, LLC
23.40%
RA Capital Management, LP
15.70%
Driehaus Capital Management, LLC
10.46%
BVF Partners L.P.
9.87%
Samsara BioCapital, LLC
7.07%
Other
33.51%
持股股東
持股股東
佔比
Third Rock Ventures, LLC
23.40%
RA Capital Management, LP
15.70%
Driehaus Capital Management, LLC
10.46%
BVF Partners L.P.
9.87%
Samsara BioCapital, LLC
7.07%
Other
33.51%
股東類型
持股股東
佔比
Venture Capital
48.85%
Hedge Fund
23.18%
Investment Advisor/Hedge Fund
16.46%
Investment Advisor
13.45%
Research Firm
3.43%
Individual Investor
2.64%
Pension Fund
0.11%
Bank and Trust
0.11%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
139
48.23M
108.24%
+566.32K
2025Q1
139
54.98M
123.75%
+8.24M
2024Q4
107
54.00M
121.73%
+28.70M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Third Rock Ventures, LLC
10.43M
23.4%
+18.86K
+0.18%
Mar 31, 2025
RA Capital Management, LP
7.00M
15.7%
--
--
Mar 31, 2025
Driehaus Capital Management, LLC
4.66M
10.46%
+1.54M
+49.23%
May 31, 2025
BVF Partners L.P.
4.40M
9.87%
+1.94M
+79.29%
Mar 31, 2025
Samsara BioCapital, LLC
3.15M
7.07%
+380.61K
+13.75%
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.20M
4.94%
--
--
Mar 31, 2025
Deep Track Capital LP
1.91M
4.29%
--
--
Mar 31, 2025
Goldman Sachs & Company, Inc.
1.45M
3.25%
-224.96K
-13.44%
Mar 31, 2025
Avoro Capital Advisors LLC
1.34M
3%
+227.50K
+20.50%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.16M
2.61%
-78.59K
-6.33%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
First Trust Multi-Manager Small Cap Opportunities ETF
0.21%
iShares Russell 2000 Value ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Global X Russell 2000 ETF
0.01%
Fidelity MSCI Health Care Index ETF
0%
Schwab U.S. Broad Market ETF
0%
iShares Health Innovation Active ETF
0%
查看更多
First Trust Multi-Manager Small Cap Opportunities ETF
佔比0.21%
iShares Russell 2000 Value ETF
佔比0.02%
iShares Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
Fidelity MSCI Health Care Index ETF
佔比0%
Schwab U.S. Broad Market ETF
佔比0%
iShares Health Innovation Active ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
